The Tubercin Colorado court proceedings:
Shinn Capital Group, Inc., Seeks Subpoenas of
Test Results for Tubercin, an Anti-Cancer and
HIV/AIDS Immunostimulant
Friday October 7, 3:44 pm ET
OKLAHOMA CITY, Okla.--(BUSINESS WIRE)--Oct. 7, 2005--Dr. Ronald
Shinn, President and CEO of Artec, Inc. (Pink Sheets: ATKJ - News ) announced
today that Shinn Capital Group, Inc. has moved the District Court in Oklahoma
City to allow it to subpoena all Tubercin samples, test reports, studies, lab notes,
protocols, statistical data, opinions and conclusions regarding studies relating to
Tubercin from the Denver Research Institute, the University of Colorado Health
Sciences Center, the Denver Veteran's Affairs Medical Center and Dr. Leland
Shapiro.
In the motion to the Court, Shinn Capital Group, Inc. states once again that it is
the lawful owner of Tubercin and that Hard to Treat Diseases, a Florida
corporation, has no lawful rights to Tubercin. Based upon information and belief,
Hard to Treat Diseases, a Florida corporation entered into a contractual agreement
with the Denver Research Institute, the University of Colorado Health Sciences
Center, the Denver Veteran's Affairs Medical Center and Dr. Leland Shapiro to
test Tubercin. Because Hard to Treat Diseases, a Florida corporation was not the
lawful owner of Tubercin, such agreement was and is void because Hard to Treat
Diseases, a Florida corporation lacked the capacity to enter into the contract.
Accordingly, Shinn Capital Group, Inc. is entitled to all Tubercin samples, test
reports, studies, lab notes, protocols, statistical data, opinions and conclusions
regarding studies relating to Tubercin and seeks to subpoena the same.
"We are aggressively pursuing Tubercin claims against Colm King, Hard to Treat
Diseases, a Florida corporation, and others both in Oklahoma and elsewhere. We
will provide you with information as those matters progress," states Gerry Knight.
Artec holds a sub-license agreement for the United States and Canada for the
development and marketing of Tubercin from Shinn Capital Group, Inc.
Artec, Inc., Oklahoma City
Gerry Knight, 405-949-1808 or 800-388-8875
www.artec-inc.net
*******************************************************
Shinn Capital Group, Inc. Files Suit in Colorado Against Several Institutions, Including Dr. Leland Shapiro, to Obtain Favorable Test Results for Tubercin, an Anti-Cancer and HIV/AIDS Immunostimulant.
Tuesday October 11, 9:24 pm ET
SACRAMENTO , Calif. --(BUSINESS WIRE)--Oct. 11, 2005--Dr. Ronald Shinn, President and CEO of Artec, Inc. (Pink Sheets: ATKJ - News ) announced today that Shinn Capital Group, Inc. has filed a friendly suit in Colorado . The suit is against the Denver Research Institute, the University of Colorado Health Sciences Center, the Denver Veteran's Affairs Medical Center and Dr. Leland Shapiro to obtain all Tubercin samples, test reports, studies, lab notes, protocols, statistical data, opinions and conclusions regarding studies relating to Tubercin.
“We believe that the Colorado test results are favorable regarding Tubercin's ability to combat both Cancer and AIDS as an Immunostimulant. Because Shinn Capital Group, Inc. is the lawful owner of Tubercin, it is entitled to these test results and has instituted a friendly lawsuit in Colorado to seek the same," states Dr. Shinn.
In addition, Shinn Capital Group, Inc. has moved the Court in Oklahoma to sanction both Colm J. King and Hard to Treat Diseases, Inc., a Florida corporation, for concealment or removal of Tubercin subject to the Court's Order of Delivery. The motion notes that Colm J. King's actions might constitute a misdemeanor subjecting him to a fine and imprisonment for a term of six (6) months, and seeks an Order that both Colm J. King and Hard to Treat Diseases, Inc. shall be liable to Shinn Capital Group, Inc. for double the amount of damage done to the property together with reasonable attorney's fees.
"We will continue to provide updates on our progress," states Gerry Knight. Artec holds a sub-license agreement for the United States and Canada for the development and marketing of Tubercin from Shinn Capital Group, Inc. You can view our web site at artec-inc.net .
Contact:
Artec, Inc.
Gerry Knight, 800-388-8875 or 405-949-1808 |
